# US 2021/0079100 A1 · Methods and compositions for treating hyperpigmentation disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0079100 A1
- Document ID: US20210079100A1
- Status: Published application
- Kind: A1
- Application number: 16/620,180
- Filed: 2018-06-07
- Published: 2021-03-18
- Earliest claimed: 2017-06-08
- Assignees: Inserm (Institute National De La Sante Et De La Recherche Medicale); Universite Nice Sophia Antipolis; Centre Hopitalier Universitaire de Nice
- Applicants: INSERM (Institute National de la Sante et de la Recherche Medicale); Universite Nice Sophia Antipolis; Centre Hopitalier Universitaire de Nice
- Inventors: Thierry PASSERON; Laura SORMANI LE BOURHIS
- Web page: https://patentgrep.com/patent/US20210079100A1

## CPC

- C07K 16/2851: {against the lectin superfamily, e.g. CD23, CD72}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 38/178: {Lectin superfamily, e.g. selectins}
- A61P 17/00: Drugs for dermatological disorders
- C12N 15/1138: {against receptors or cell surface proteins}
- G01N 33/5041: {involving analysis of members of signalling pathways}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/531: Stem-loop; Hairpin
- C12N 2740/15043: viral genome or elements thereof as genetic vector
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to a method for treating hyperpigmentary skin disorder. By using normal human melanocytes (NHMs) and normal human keratinocytes (NHKs), which are infected with CLEC12B siRNA/shRNA/RNAi lentiviral particles, inventors have showed that decreasing CLEC12B expression significantly reduce the transfer of melanin to the keratinocytes. These results demonstrate that CLEC12B is specifically expressed in the skin by melanocytes and plays a key role in the transfer or melanosomes to the keratinocytes. Accordingly, the invention relates to a method for treating hyperpigmentary skin disorder in a subject in need thereof comprising a step of administering to said subject a therapeutically effective amount of a CLEC12B antagonist, wherein CLEC12B antagonist is polypeptide, more particularly a decoy.

## Claims

### Claim 1

A method for treating hyperpigmentary skin disorder in a subject in need thereof comprising a step of administering to said subject a therapeutically effective amount of a CLEC12B antagonist.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the CLEC12B antagonist is an antibody.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the CLEC12B antagonist is a polypeptide.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the the polypeptide is a decoy.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the CLEC12B antagonist is a glycomimectic molecule.

### Claim 6

A method of screening a drug suitable for the treatment of hyperpigmentary skin disorder comprising i) providing a test compound and ii) determining the ability of said test compound to inhibit the activity of CLEC12B.
